
McKesson Corporation
NYSE•MCK
CEO: Mr. Brian S. Tyler Ph.D.
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1994-11-10
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Contact Information
Market Cap
$102.02B
P/E (TTM)
25.2
32.5
Dividend Yield
0.4%
52W High
$895.58
52W Low
$570.51
52W Range
Rank12Top 1.7%
6.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2026 Data
Revenue
$103.15B+10.14%
4-Quarter Trend
EPS
$8.95+378.61%
4-Quarter Trend
FCF
$2.53B+34.48%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Six Months Revenue Growth Six months revenues increased 16% to $201.0B USD, driven by North American Pharmaceutical volume growth.
Net Income Surges Three months net income attributable to McKesson Corporation surged 361% to $1.11B USD, reflecting strong operational leverage.
Strong EPS Performance Diluted EPS for six months reached $15.16 USD, reflecting a substantial 71% increase over prior period.
Major Acquisition Funding Completed $3.37B USD in major acquisitions, including Core Ventures and PRISM Vision during the period.
Risk Factors
Substantial Litigation Liability Total litigation liabilities remain substantial at $5.72B USD as of September 30, 2025 reporting date.
Widening Stockholders' Deficit Total stockholders' deficit widened to $(1.36)B USD at September 30, 2025, reflecting accumulated losses.
Significant Bad Debt Provision Recognized a significant $189M USD provision for bad debts related to customer Rite Aid bankruptcy.
Restructuring Charge Execution Recorded $110M USD in restructuring charges for six months tied to technology service model modernization.
Outlook
Liquidity Position Secure Available cash and credit facilities provide sufficient liquidity for short-term and long-term capital needs.
Medical-Surgical Separation Planned Announced intention to separate Medical-Surgical Solutions segment into an independent company effective May 8, 2025.
Dividend Increase Signals Confidence Quarterly dividend raised to $0.82 USD per share from $0.71 USD, signaling confidence in future earnings.
Debt Issuance for Growth Issued $2.0B USD in new notes to fund Core Ventures acquisition, managing debt maturity profile.
Peer Comparison
Revenue (TTM)
CVS$394.08B
MCK$387.09B
$321.33B
Gross Margin (Latest Quarter)
VRTX86.5%
GSK73.6%
BMY71.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MDT | $129.39B | 27.1 | 9.8% | 31.9% |
| VRTX | $120.10B | 32.6 | 21.8% | 7.4% |
| BMY | $111.25B | 18.4 | 34.7% | 52.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.7%
Moderate Growth
4Q Net Income CAGR
8.1%
Profitability Improving
Cash Flow Stability
50%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 4, 2026
EPS:$9.19
|Revenue:$105.91B
Reports
All Years
Form 10-Q - Q2 2026
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $103.15B+10.1%|EPS: $8.95+378.6%MeetForm 10-Q - Q1 2026
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $97.83B+23.4%|EPS: $6.28-10.9%MissForm 10-K - FY 2025
Period End: Mar 31, 2025|Filed: May 9, 2025|Revenue: $359.05B+16.2%|EPS: $25.86+14.7%BeatForm 10-Q - Q3 2025
Period End: Dec 31, 2024|Filed: Feb 6, 2025|Revenue: $95.29B+17.8%|EPS: $6.98+56.9%MissForm 10-Q - Q2 2025
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $93.65B+21.3%|EPS: $1.87-62.2%MissForm 10-Q - Q1 2025
Period End: Jun 30, 2024|Filed: Aug 7, 2024|Revenue: $79.28B+6.4%|EPS: $7.05-0.3%MissForm 10-K - FY 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $308.95B+11.7%|EPS: $22.54-10.7%MissForm 10-Q - Q3 2024
Period End: Dec 31, 2023|Filed: Feb 8, 2024|Revenue: $80.90B+14.8%|EPS: $4.45-42.3%Miss